Perioperative IFN-α to avoid surgically induced immune suppression in colorectal cancer patients

Histology and Histopathology

Volumn 21, Issue 7-9, 2006, Pages 753-760

  Oosterling, S J ^a   van der Bij, G J ^a   Mels, A K ^a   Beelen, R H J ^a   Meijer, S ^a   Van Egmond, M ^a   van Leeuwen, P A M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal Cancer; Immune function; Interferon (IFN ); Surgery

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; FLUOROURACIL; FOLINIC ACID; INTERFERON ANTIBODY; PEGINTERFERON; PHYTOHEMAGGLUTININ; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; BIOLOGICAL RESPONSE MODIFIER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL CYCLE REGULATION; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DRUG ELIMINATION; DRUG POTENTIATION; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; LAPAROTOMY; LIVER BIOPSY; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; REVIEW; SIGNAL TRANSDUCTION; SKIN TEST; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; COLORECTAL TUMOR; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; POSTOPERATIVE COMPLICATION;

BIOLOGICAL RESPONSE MODIFIERS; COLORECTAL NEOPLASMS; HUMANS; IMMUNOSUPPRESSION; INTERFERON-ALPHA; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS;

EID: 33645794511     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Corfu-A study group (1995). Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. J. Clin. Oncol. 13, 921-928.
2. Atzpodien J., Kirchner H., Jonas U., Bergmann L., Schott H., Heynemann H., Fornara P., Loening S.A., Roigas J., Muller S.C., Bodenstein H., Pomer S., Metzner B., Rebmann U., Oberneder R., Siebels M., Wandert T., Puchberger T. and Reitz M. (2004). Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively randomized trial of the german cooperative renal carcinoma chemoimmunotherapy group (DGCIN). J. Clin. Oncol. 22, 1188-1194.
3. Balkwill F.R. and Oliver R.T. (1977). Growth inhibitory effects of interferon on normal and malignant human haemopoietic cells. Int. J. Cancer 20, 500-505.
4. Belardelli F. and Ferrantini M. (2002). Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23, 201-208.
5. Belardelli F. and Gresser I. (1996). The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 17, 369-372.
6. Belardelli F., Ferrantini M., Proietti E. and Kirkwood J.M. (2002). Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 119-134.
7. Biron C.A. (2001). Interferons alpha and beta as immune regulators - a new look. Immunity 14, 661-664.
8. Bosch B., Guller U., Schnider A., Maurer R., Harder F., Metzger U. and Marti W.R. (2003). Perioperative detection of disseminated tumour cells is an independent prognostic factor in patients with colorectal cancer. Br. J. Surg. 90, 882-888.
9. Bouvy N.D., Marquet R.L., Jeekel J. and Bonjer H.J. (1997). Laparoscopic surgery is associated with less tumour growth stimulation than conventional surgery: an experimental study. Br. J. Surg. 84, 358-361.
10. Brassard D.L., Grace M.J. and Bordens R.W. (2002). Interferon-alpha as an immunotherapeutic protein. J. Leukoc. Biol. 71, 565-581.
11. Clausen J., Vergeiner B., Enk M., Petzer A.L., Gastl G. and Gunsilius E. (2003). Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology 207, 85-93.
12. Clemens M.J. (2003). Interferons and apoptosis. J. Interferon Cytokine Res. 23, 277-292.
13. Delves P.J. and Roitt I.M. (2000). The immune system. First of two parts. N. Engl. J. Med. 34, 37-49.
14. Faist E., Schinkel C. and Zimmer S. (1996). Update on the mechanisms of immune suppression of injury and immune modulation. World J. Surg. 20, 454-459.
15. Ferrantini M., Giovarelli M., Modesti A., Musiani P., Modica A., Venditti M., Peretti E., Lollini P.L., Nanni P. and Forni G. (1994). IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/ A). results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J. Immunol. 153: 4604-4615.
16. Ferrantini M., Proietti E., Santodonato L., Gabriele L., Peretti M., Plavec I., Meyer F., Kaido T., Gresser I. and Belardelli F. (1993). Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res. 53, 1107-1112.
17. Finkelman F.D., Svetic A., Gresser I., Snapper C., Holmes J., Trotta P.P., Katona I.M. and Gause W.C. (1991). Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J. Exp. Med. 174, 1179-1188.
18. Gabriele L., Kaido T., Woodrow D., Moss J., Ferrantini M., Proletti E., Santodonato L., Rozera C., Maury C. and Belardelli F. (1995). Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells. Am. J. Pathol. 147, 445-460.
19. Gresser I. and Belardelli F. (2002). Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev. 13, 111-118.
20. Gresser I., Belardelli F., Maury C., Maunoury M.T. and Tovey M.G. (1983). Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J. Exp. Med. 158, 2095-2107.
21. Gupta A. and Watson D.I. (2001). Effect of laparoscopy on immune function. Br. J. Surg. 88, 1296-1306.
22. Hakansson A., Gustafsson B., Krysander L. and Hakansson L. (1998). Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J. Interferon Cytokine Res. 18, 33-39.
23. Hausmaninger H., Moser R., Samonigg H., Mlineritsch B., Schmidt H., Pecherstorfer M., Fridrik M., Kopf C., Nitsche D., Kaider A. and Ludwig H. (1999). Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study. Eur. J. Cancer 35, 380-385.
24. Houvenaeghel G., Bladou F., Blache J.L., Olive D., Monges G., Jacquemier J., Chaudet H., Delpero J.R. and Guerinel G. (1997). Tolerance and feasibility of perioperative treatment with interferon-alpha 2a in advanced cancers. Int. Surg 82, 165-169.
25. Jewett A. and Bonavida B. (1995). Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J. Clin. Immunol. 15, 35-44.
26. Kaido T., Bandu M.T., Maury C., Ferrantini M., Belardelli F. and Gresser I. (1995). IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int. J. Cancer 60, 221-229.
27. Kaido T., Maury C., Schirrmacher V. and Gresser I. (1994). Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta. Int. J. Cancer 57, 538-543.
28. Kamath A.T., Sheasby C.E. and Tough D.F. (2005). Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J. Immunol. 174: 767-776.
29. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Ernstoff M.S. and Rao U. (2001). High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19, 2370-2380.
30. Kirkwood J.M., Richards T., Zarour H.M., Sosman J., Ernstoff M., Whiteside T.L., Ibrahim J., Blum R., Wieand S. and Mascari R. (2002). Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95, 1101-1112.
31. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C. and Blum R.H. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7-17.
32. Kosmidis P.A., Baxevanis C.N., Tsavaris N., Papanastasiou M., Anastasopoulos E., Bacoyiannis C., Mylonakis N., Karvounis N., Bafaloukos D. and Karabelis A. (1992). The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b. J. Clin. Oncol. 10, 1153-1157.
33. Leung K.L., Tsang K.S., Ng M.H., Leung K.J., Lai P.B., Lee J.F. and Lau W.Y. (2003). Lymphocyte subsets and natural killer cell cytotoxicity after laparoscopically assisted resection of rectosigmoid carcinoma. Surg. Endosc. 17, 1305-1310.
34. Liang S., Wei H., Sun R. and Tian Z. (2003). IFNalpha regulates NK cell cytotoxicity through STAT1 pathway. Cytokine 23, 190-199.
35. Marrack P., Kappler J. and Mitchell T. (1999). Type I interferons keep activated T cells alive. J. Exp. Med. 189, 521-530.
36. Matarrese P., Di Biase L., Santodonato L., Straface E., Mecchia M., Ascione B., Parmiani G., Belardelli F., Ferrantini M. and Malorni W. (2002). Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function. Am. J. Pathol. 160, 1507-1520.
37. Mels A.K., Statius Muller M.G., van Leeuwen P.A., von Blomberg B.M., Scheper R.J., Cuesta M.A., Beelen R.H. and Meijer S. (2001). Immune-stimulating effects of low-dose perioperative recombinant granulocyte-macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma. Br. J. Surg. 88, 539-544.
38. Montoya M., Schiavoni G., Mattei F., Gresser I., Belardelli F., Borrow P. and Tough D.F. (2002). Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99, 3263-3271.
39. Nichols P.H., Ramsden C.W., Ward U., Trejdosiewicz L.K., Ambrose N.S. and Primrose J.N. (1993). Peri-operative modulation of cellular immunity in patients with colorectal cancer. Clin. Exp. Immunol. 94, 4-10.
40. Nichols P.H., Ward U., Ramsden C.W. and Primrose J.N. (1994). The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer. Br. J. Cancer 70, 946-949.
41. Palmer K.J., Harries M., Gore M.E. and Collins M.K. (2000). Interferon-alpha (IFN-alpha). stimulates anti-melanoma cytotoxic T lymphocyte (CTL). generation in mixed lymphocyte tumour cultures (MLTC). Clin. Exp. Immunol. 119, 412-418.
42. Porta C., Hadj-Slimane R., Nejmeddine M., Pampin M., Tovey M.G., Espert L., Alvarez S. and Chelbi-Alix M.K. (2005). Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively. Oncogene 24: 605-615.
43. Raa S.T., Oosterling S.J., van der Kaaij N.P., van den Tol M.P., Beelen R.H., Meijer S., van Eijck C.H., van der.Sijn., Jr., van Egmond M., Jeekel J. (2005). Surgery promotes implantation of disseminated tumor cells, but does not increase growth of tumor cell clusters. J. Surg. Oncol. 92, 124-129.
44. Ralph P., Nakoinz I. and Rennick D. (1988). Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity. J. Exp. Med. 167, 712-717.
45. Reid L.M., Minato N., Gresser I., Holland J., Kadish A. and Bloom B.R. (1981). Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice. Proc. Natl. Acad. Sci. USA 78, 1171-1175.
46. Rogers E., Bredin H., Butler M., Corcoran M., Egan E., Fennelly J., Grainger R., Aleer S.M., Dermott T.M., Mullins G., Tanner A., Twomey A. and Thornhill J. (2000). Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the Multicentre All Ireland Immunotherapy Study Group. Eur. Urol. 37, 261-266.
47. Salazar-Mather T.P., Ishikawa R. and Biron C.A. (1996). NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection. J. Immunol. 157, 3054-3064.
48. Sales J.P., Wind P., Douard R., Cugnenc P.H. and Loric S. (1999). Blood dissemination of colonic epithelial cells during no-touch surgery for rectosigmoid cancer. Lancet 354, 392
49. Schott A., Vogel I., Krueger U., Kalthoff H., Schreiber H.W., Schmiegel W., Henne-Bruns D., Kremer B. and Juhl H. (1998). Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann. Surg. 227, 372-379.
50. Sedman P.C., Ramsden C.W., Brennan T.G., Giles G.R. and Guillou P.J. (1988). Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses. Br. J. Surg. 75, 976-981.
51. Sietses C., Beelen R.H., Meijer S. and Cuesta M.A. (1999). Immunological consequences of laparoscopic surgery, speculations on the cause and clinical implications. Langenbecks Arch. Surg. 384, 250-258.
52. Sietses C., Cuesta M., Beelen R.H. and von Blomberg B.M. (2000). Laparoscopic techniques preserve immune function during and after surgery. Ann. Surg. 232, 719
53. Tagliaferri P., Caraglia M., Budillon A., Marra M., Vitale G., Viscomi C., Masciari S., Tassone P., Abbruzzese A. and Venuta S. (2005). New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha). treatment of human cancer. Cancer Immunol. Immunother. 54, 1-10.
54. Tough D.F., Borrow P. and Sprent J. (1996). Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272, 1947-1950.
55. Wenner C.A., Guler M.L., Macatonia S.E., O'Garra A. and Murphy K.M. (1996). Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J. Immunol. 156, 1442-1447.
56. Ziegler S.F., Ramsdell F. and Alderson M.R. (1994). The activation antigen CD69. Stem Cells 12, 456-465.